Briefing report, page-8

Sometimes someone posts something so good there isn't much more left to say. Great job Rbx.

NOX is a high volatility stock due to the nature of it being an early phase biotech, that applies to the upside as well

I found the clinical results of CEP to be pretty solid. It's a phase one trial in late stage cancer of various types, showing many cases of stable disease after 6 mo. Definitely gives promise for follow up.

This is not an expensive immunotherapy it should be remembered, but something far more accessible. Which as Rbx added, may have neuroprotective qualities in addition.

Still very early but very promising is my takeaway.

Looking forward to this week's update.